Hadrien P.
- Country
- France
- Department
- Anesthésie et Réanimation
Research Overview
Data & Insights
Has run more than one trial at 0 of 7 partner sites.
Specializations
Gastrointestinal Oncology
Focus on malignant diseases of the digestive tract. Studies include colorectal cancer. Additional work addresses pancreatic adenocarcinoma. Research also covers biliary tract carcinoma.
- Adjuvant chemotherapy strategies
- Neoadjuvant chemoradiation protocols
- Organ preservation techniques
- Targeted therapy for FGFR‑altered tumors
Contributions aim to improve disease‑free survival and postoperative outcomes.
Breast Cancer Therapeutics
Investigation of hormone‑responsive tumors such as ER‑positive, HER2‑negative breast cancer across metastatic and early‑stage settings.
- CDK4/6 inhibitor combinations
- PI3K pathway targeting
- Antibody‑drug conjugate application
- Circulating tumor DNA–guided treatment decisions
Efforts emphasize extending progression‑free intervals and reducing relapse risk.
Prostate Cancer and Hormonal Oncology
Study of advanced disease forms such as castration‑resistant prostate cancer and associated cardiovascular adjuncts.
- Combination of aspirin with statin therapy
- Evaluation of survival endpoints
- Integration of metabolic modulation in oncology care
Research aligns oncologic control with systemic health preservation.
Perioperative and Anesthesia Innovations
Addressing surgical complications through techniques like intraoperative fluorescence angiography. Analgesic strategies include the erector spinae plane block for acute low back pain. Vasopressor strategy comparison targets vasoplegic syndrome in cardiac surgery.
- Vasopressor strategy comparison for vasoplegic syndrome
- Erector spinae plane block for acute low back pain
- Perfusion assessment to prevent anastomotic leakage
These initiatives target immediate postoperative safety and pain management.
Molecularly Targeted and Precision Medicine
Implementation of biomarker‑driven approaches for tumors harboring BRAF V600E. Research also targets FGFR alterations using genomic profiling.
- FGFR inhibitor versus physician’s choice comparisons
- BRAF‑targeted neoadjuvant regimens
- ctDNA monitoring for therapeutic adaptation
- Personalized escalation based on molecular response
Focus is on enhancing efficacy through genomic insight.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.